Hepatitis Monthly

Published by: Kowsar

Plasma Level of miR-5193 as a Novel Biomarker for Diagnosis of HBV-Related Hepatocellular Carcinoma

Niloofar Moradi 1 , Mahdi Paryan 2 , * , Behzad Khansarinejad 3 , Hossein Sarmadian 4 and Mahdieh Mondanizadeh 1 , 5 , **
Authors Information
1 Department of Biotechnology and Molecular Medicine, Arak University of Medical Sciences, Arak, Iran
2 Department of Research and Development, Production and Research Complex, Pasteur Institute of Iran, Tehran, Iran
3 Department of Microbiology and Immunology, Arak University of Medical Sciences, Arak, Iran
4 Infectious Diseases Research Center, Arak University of Medical Sciences, Arak, Iran
5 Molecular and Medicine Research Center, Arak University of Medical Sciences, Arak, Iran
Corresponding Authors:
Article information
  • Hepatitis Monthly: February 28, 2019, 19 (2); e84455
  • Published Online: February 24, 2019
  • Article Type: Research Article
  • Received: September 21, 2018
  • Revised: January 19, 2019
  • Accepted: February 14, 2019
  • DOI: 10.5812/hepatmon.84455

To Cite: Moradi N , Paryan M, Khansarinejad B , Sarmadian H, Mondanizadeh M. Plasma Level of miR-5193 as a Novel Biomarker for Diagnosis of HBV-Related Hepatocellular Carcinoma, Hepat Mon. 2019 ; 19(2):e84455. doi: 10.5812/hepatmon.84455.

Abstract
Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Vallet-Pichard A, Pol S. Hepatitis B virus treatment beyond the guidelines: Special populations and consideration of treatment withdrawal. Therap Adv Gastroenterol. 2014;7(4):148-55. doi: 10.1177/1756283X14524614. [PubMed: 25057295]. [PubMed Central: PMC4107707].
  • 2. World Health Organization. Hepatitis B. 2018. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.
  • 3. Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am. 2015;24(1):1-17. doi: 10.1016/j.soc.2014.09.001. [PubMed: 25444466].
  • 4. Akamatsu S, Hayes CN, Tsuge M, Miki D, Akiyama R, Abe H, et al. Differences in serum microRNA profiles in hepatitis B and C virus infection. J Infect. 2015;70(3):273-87. doi: 10.1016/j.jinf.2014.10.017. [PubMed: 25452043].
  • 5. Zhang Y, Wei C, Guo CC, Bi RX, Xie J, Guan DH, et al. Prognostic value of microRNAs in hepatocellular carcinoma: A meta-analysis. Oncotarget. 2017;8(63):107237-57. doi: 10.18632/oncotarget.20883. [PubMed: 29291025]. [PubMed Central: PMC5739810].
  • 6. Wang Y, Gao Y, Shi W, Zhai D, Rao Q, Jia X, et al. Profiles of differential expression of circulating microRNAs in hepatitis B virus-positive small hepatocellular carcinoma. Cancer Biomark. 2015;15(2):171-80. doi: 10.3233/CBM-140451. [PubMed: 25519019].
  • 7. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264-1273 e1. doi: 10.1053/j.gastro.2011.12.061. [PubMed: 22537432]. [PubMed Central: PMC3338949].
  • 8. Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64(1 Suppl):S84-S101. doi: 10.1016/j.jhep.2016.02.021. [PubMed: 27084040].
  • 9. Tang Q, Wang Q, Zhang Q, Lin SY, Zhu Y, Yang X, et al. Gene expression, regulation of DEN and HBx induced HCC mice models and comparisons of tumor, para-tumor and normal tissues. BMC Cancer. 2017;17(1):862. doi: 10.1186/s12885-017-3860-x. [PubMed: 29254483]. [PubMed Central: PMC5735680].
  • 10. Sun Q, Wang R, Wang Y, Luo J, Wang P, Cheng B. Notch1 is a potential therapeutic target for the treatment of human hepatitis B virus X protein-associated hepatocellular carcinoma. Oncol Rep. 2014;31(2):933-9. doi: 10.3892/or.2013.2917. [PubMed: 24336972].
  • 11. Wang F, Zhou H, Yang Y, Xia X, Sun Q, Luo J, et al. Hepatitis B virus X protein promotes the growth of hepatocellular carcinoma by modulation of the Notch signaling pathway. Oncol Rep. 2012;27(4):1170-6. doi: 10.3892/or.2012.1620. [PubMed: 22218807]. [PubMed Central: PMC3583435].
  • 12. Wang F, Xia X, Wang J, Sun Q, Luo J, Cheng B. Notch1 signaling contributes to the oncogenic effect of HBx on human hepatic cells. Biotechnol Lett. 2013;35(1):29-37. doi: 10.1007/s10529-012-1048-7. [PubMed: 22986536].
  • 13. Xu J, Yun X, Jiang J, Wei Y, Wu Y, Zhang W, et al. Hepatitis B virus X protein blunts senescence-like growth arrest of human hepatocellular carcinoma by reducing Notch1 cleavage. Hepatology. 2010;52(1):142-54. doi: 10.1002/hep.23613. [PubMed: 20578140].
  • 14. Sun Q, Wang R, Luo J, Wang P, Xiong S, Liu M, et al. Notch1 promotes hepatitis B virus X protein-induced hepatocarcinogenesis via Wnt/beta-catenin pathway. Int J Oncol. 2014;45(4):1638-48. doi: 10.3892/ijo.2014.2537. [PubMed: 25017705].
  • 15. Gao J, Xiong Y, Wang Y, Wang Y, Zheng G, Xu H. Hepatitis B virus X protein activates Notch signaling by its effects on Notch1 and Notch4 in human hepatocellular carcinoma. Int J Oncol. 2016;48(1):329-37. doi: 10.3892/ijo.2015.3221. [PubMed: 26530164].
  • 16. Koberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhag J, et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer. 2013;49(16):3442-9. doi: 10.1016/j.ejca.2013.06.002. [PubMed: 23810247].
  • 17. Lou J, Zhang L, Lv S, Zhang C, Jiang S. Biomarkers for hepatocellular carcinoma. Biomark Cancer. 2017;9:1-9. doi: 10.1177/1179299X16684640. [PubMed: 28469485]. [PubMed Central: PMC5345949].
  • 18. Mao B, Wang G. MicroRNAs involved with hepatocellular carcinoma (review). Oncol Rep. 2015;34(6):2811-20. doi: 10.3892/or.2015.4275. [PubMed: 26398882].
  • 19. Giordano S, Columbano A. MicroRNAs: New tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology. 2013;57(2):840-7. doi: 10.1002/hep.26095. [PubMed: 23081718].
  • 20. Abedi N, Mohammadi-Yeganeh S, Koochaki A, Karami F, Paryan M. miR-141 as potential suppressor of beta-catenin in breast cancer. Tumour Biol. 2015;36(12):9895-901. doi: 10.1007/s13277-015-3738-y. [PubMed: 26164002].
  • 21. Endzelins E, Melne V, Kalnina Z, Lietuvietis V, Riekstina U, Llorente A, et al. Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: A systematic review. Mol Cancer. 2016;15(1):41. doi: 10.1186/s12943-016-0523-5. [PubMed: 27189160]. [PubMed Central: PMC4870749].
  • 22. Tan Y, Ge G, Pan T, Wen D, Chen L, Yu X, et al. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS One. 2014;9(9). e107986. doi: 10.1371/journal.pone.0107986. [PubMed: 25238238]. [PubMed Central: PMC4169601].
  • 23. Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol. 2011;29(36):4781-8. doi: 10.1200/JCO.2011.38.2697. [PubMed: 22105822].
  • 24. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33(20). e179. doi: 10.1093/nar/gni178. [PubMed: 16314309]. [PubMed Central: PMC1292995].
  • 25. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002;30(9). e36. doi: 10.1093/nar/30.9.e36. [PubMed: 11972351]. [PubMed Central: PMC113859].
  • 26. Wang J, Chen J, Sen S. MicroRNA as biomarkers and diagnostics. J Cell Physiol. 2016;231(1):25-30. doi: 10.1002/jcp.25056. [PubMed: 26031493].
  • 27. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol. 2011;45(4):355-60. doi: 10.1097/MCG.0b013e3181f18ac2. [PubMed: 21278583].
  • 28. Pan JH, Zhou H, Zhao XX, Ding H, Li W, Qin L, et al. Role of exosomes and exosomal microRNAs in hepatocellular carcinoma: Potential in diagnosis and antitumour treatments (review). Int J Mol Med. 2018;41(4):1809-16. doi: 10.3892/ijmm.2018.3383. [PubMed: 29328436]. [PubMed Central: PMC5810235].
  • 29. Wang X, Chen J, Li F, Lin Y, Zhang X, Lv Z, et al. MiR-214 inhibits cell growth in hepatocellular carcinoma through suppression of beta-catenin. Biochem Biophys Res Commun. 2012;428(4):525-31. doi: 10.1016/j.bbrc.2012.10.039. [PubMed: 23068095].
  • 30. Li Y, Li Y, Chen Y, Xie Q, Dong N, Gao Y, et al. MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis. Cancer Cell Int. 2017;17:102. doi: 10.1186/s12935-017-0471-1. [PubMed: 29151817]. [PubMed Central: PMC5678695].
  • 31. Yang Y, Chang S, Zhao Z, Hou NI, He K, Wang X, et al. MicroRNA-214 suppresses the proliferation of human hepatocellular carcinoma cells by targeting E2F3. Oncol Lett. 2015;10(6):3779-84. doi: 10.3892/ol.2015.3745. [PubMed: 26788207]. [PubMed Central: PMC4665883].
  • 32. McDonald AC, Vira M, Shen J, Sanda M, Raman JD, Liao J, et al. Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer. Prostate. 2018;78(6):411-8. doi: 10.1002/pros.23485. [PubMed: 29383739].
  • 33. Freres P, Bouznad N, Servais L, Josse C, Wenric S, Poncin A, et al. Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC Cancer. 2018;18(1):102. doi: 10.1186/s12885-018-4015-4. [PubMed: 29378531]. [PubMed Central: PMC5789542].
  • 34. Xiang ZL, Zhao XM, Zhang L, Yang P, Fan J, Tang ZY, et al. MicroRNA-34a expression levels in serum and intratumoral tissue can predict bone metastasis in patients with hepatocellular carcinoma. Oncotarget. 2016;7(52):87246-56. doi: 10.18632/oncotarget.13531. [PubMed: 27893432]. [PubMed Central: PMC5349985].
  • 35. Long LM, Zhan JK, Wang HQ, Li S, Chen YY, Liu YS. The clinical significance of miR-34a in pancreatic ductal carcinoma and associated molecular and cellular mechanisms. Pathobiology. 2017;84(1):38-48. doi: 10.1159/000447302. [PubMed: 27458977].
  • 36. Khlaiphuengsin A, T. Thienprasert NP , Tangkijvanich P, Posuwan N, Makkoch J, Poovorawan Y, et al. Human miR-5193 triggers gene silencing in multiple genotypes of hepatitis B virus. Microrna. 2015;4(2):123-30. [PubMed: 26456535].
  • 37. Sayad B, Naderi Y, Alavian SM, Najafi F, Janbakhsh A, Mansouri F, et al. Hepatitis D virus infection in Kermanshah, west of Iran: seroprevalence and viremic infections. Gastroenterol Hepatol Bed Bench. 2018;11(2):145-52. [PubMed: 29910856]. [PubMed Central: PMC5990919].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments